Back to News
Market Impact: 0.15

February 27th Options Now Available For Humana (HUM)

HUMNDAQ
Futures & OptionsDerivatives & VolatilityHealthcare & BiotechCompany FundamentalsMarket Technicals & FlowsInvestor Sentiment & Positioning
February 27th Options Now Available For Humana (HUM)

The note outlines two Humana (HUM) option strategies: selling a $270 put (bid $12.00) which would obligate purchase at $270 and produce a $258.00 net cost basis versus the current $279.73 share price, with the put ~3% out-of-the-money and a 62% chance to expire worthless; that premium equates to a 4.44% return on cash (32.44% annualized, “YieldBoost”). The covered-call example sells the $290 call (bid $13.30) against shares bought at $279.73, representing an 8.43% total return if called at the Feb 27 expiration, the $290 strike ~4% OTM with a 53% chance to expire worthless and a 4.75% premium boost (34.71% annualized). Implied volatility on both contracts is ~50% versus a trailing 12‑month realized volatility of 44%.

Analysis

Market structure: Short-dated option sellers are the clear near-term beneficiaries — cash‑secured put sellers and covered‑call writers can pocket a 4–5% yield over ~30 days (annualized 32–35%) because IV (~50%) sits ~6pts above realized vol (~44%). That premium suggests demand for income strategies and/or one-off risk hedging; it does not materially change HUM’s competitive position in Medicare Advantage but it compresses effective financing costs for yield hunters. Cross‑asset: this is a localized volatility premium play with negligible direct bond/FX impact, though a sharp healthcare‐policy shock would reprice credit spreads and sector correlations quickly. Risk assessment: Tail risks are regulatory (CMS MA rate cuts >2%), major litigation, or a market shock that forces assignment into a falling stock; any of these could erase the premium and produce >15–30% equity losses. Near term (days–weeks) delta/assignment and IV spikes dominate; medium term (quarters) MA enrollment and margin trends matter; long term depends on policy and demographic flows. Hidden dependencies include liquidity to meet assignment and option gamma into expiration; catalysts include upcoming Humana earnings and CMS rulemaking in the next 30–90 days that could move IV ±10+ pts. Trade implications: Direct plays: favor short-dated, cash‑secured short puts (270 Feb27) or buy-and-covered-call (buy @279.73, sell 290 Feb27) to harvest rich premium while capping required capital; size at modest weights (1–3% portfolio each). If scaling, buy protection (3‑month 240–250 puts at ~outreach sizes 20–30% notional) or use defined‑risk iron‑condors instead of naked shorts. Entry window: execute within next 7 trading days while IV premium holds; exit/roll if IV compresses >8 pts or HUM moves >7% against you. Contrarian angles: Consensus treats these trades as free yield but underestimates assignment/liquidity friction and policy tail risk; the premium advantage can be mispriced if a government reimbursement surprise occurs. Historical parallels (MA rule windows) show short‑dated premium sells profitable absent regulatory shocks, but disastrous if a >5% unexpected MA cut hits. Unintended consequence: repeated assignment into long equity during a market drawdown that ties up capital and forces forced selling elsewhere.